Clinical Trials Browser

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07144657 2025-08-27

GastricMALToma

Phase 2 Not yet recruiting

40 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT07024147 2025-06-17

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

Phase 1 Not yet recruiting

20 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT06793189 2025-01-27

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

Phase 2 Not yet recruiting

145 enrolled

Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT05923502 2023-10-23

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)

Not yet recruiting

200 enrolled

LymphoidOther hematologic neoplasm

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone

Clinical Trials

Archonc-001

Molecular and Cellular Characterization of MALT Lymphoma

Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone Lymphoma

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

GastricMALToma

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL

(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)